

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 13th January 2023

To,
The Manager
Listing Department
BSE Limited
Bombay Stock Exchange
P.J. Towers, Dalal Street
Mumbai - 400 001.

Ref: Scrip Code 956084 and ISIN INE988W07019

Subject: Submission under Regulation 52(1),52(2), 52(4), 52(7) of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.


Dear Sir/Ma'am,

With reference to the subject matter, Please find enclosed the following:

- i. Unaudited Quarterly and Year to date Financial Results for the Quarter ended 30th September 2022 and Limited review report thereon.
- ii. The disclosure of the items as required under Regulation 52(4) of SEBI (LODR), 2015.
- iii. A disclosure under Regulation 54 (2) of SEBI (LODR), 2015.
- iv. Security Cover Certificate under Regulation 56(1)(d) of SEBI (LODR),2015.

Please take the above information on your records.

For and on behalf of
For Genlink Pharma Solutions Private Limited



Itishree Garg
Company Secretary and Compliance Officer
Membership No. A 46259



Independent Auditor's Limited Review Report on the Quarterly Unaudited Financial Results of the Company for the quarter ended 30th September, 2022 pursuant to the Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to

The Board of Directors

Genlink Pharma Solutions Private Limited

Re: Limited Review Report of the Unaudited Financial Results for the quarter ended 30th September, 2022 and year to date from 1st April, 2022 to 30th September, 2022.

1. We have reviewed the accompanying statement of Unaudited Financial Results of **Genlink Pharma Solutions Private Limited**, ("the Company"), for the quarter ended 30th September, 2022 and year to date from 1st April, 2022 to 30th September, 2022 ("the Statement"), attached herewith being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the regulation') as amended (the "Listing Regulation").
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ('Ind AS 34') "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company, management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India.
4. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Shankarlal Jain & Associates LLP
Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

5. Based on our review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR SHANKARLAL JAIN & ASSOCIATES LLP,
CHARTERED ACCOUNTANTS
FIRM REG NO: - 109901W/W100082

SATISH JAIN
PARTNER
MEMBERSHIP NO.: 048874
UDIN: 23048874BGTMB1640



Place: Mumbai
Date : 13-01-2023

Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

To,
Stock Exchange (s)

As per operational circular - SEBI/HO/DDHS/DDHS_Div1/P/CIR/2022/0000000103 dated July 29, 2022 issued by Securities Exchange Board of India (SEBI) requiring to furnish Statement of Assets and Liabilities of the entity, based on examination of books of accounts and other relevant records/documents of **GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**, (CIN: U74110MH2016PTC280765) having its registered office at 1701, 17th Floor, Kesar Solitaire, Plot No 5, Sector 19, Sanpada, Navi Mumbai – 400 705, Maharashtra, India, given below is the Statement of Assets & Liabilities for half year ending on 30th September 2022 which is subject to audit: -

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED		
Statement of Assets & Liabilities		(Amount in INR)
Particulars	As at 30 Sept 2022 Unaudited	As at 31 March 2022 Audited
I. ASSETS		
1 Non-current assets		
(a) Property, Plant & Equipment & Intangible Ass	2,86,29,606	2,88,97,971
(b) Non-current investments	24,89,95,479	24,89,95,479
2 Current assets		
(a) Trade receivables	-	-
(b) Cash and cash equivalents	3,393	57,43,810
(c) Loans	50,38,000	-
(d) Other current assets	13,40,827	11,35,056
TOTAL	28,40,07,305	28,47,72,315
II. EQUITY AND LIABILITIES		
1 Equity		
(a) Share capital	1,00,000	1,00,000
(b) Reserves & Surplus	44,41,994	38,98,695
2 Non-current liabilities		
(a) Financial Liabilities		
(i) Long-term borrowings	2,27,62,341	2,21,14,531
3 Current liabilities		
(a) Financial Liabilities		
(i) Trade payables	1,59,640	77,576
(ii) Other financial liabilities	25,66,264	31,33,753
(b) Short-term borrowings	25,27,18,967	25,46,62,881
(c) Current tax liabilities & Provisions	4,12,750	2,57,500
(d) Other Current liabilities	8,45,348	5,27,379
TOTAL	28,40,07,305	28,47,72,315



Place: Mumbai
Date : 13/01/2023

FOR SHANKARLAL JAIN & ASSOCIATES LLP
CHARTARED ACCOUNTANTS
FIRM REG NO. 109901W/W100082

Jain S.

SATISH JAIN
Partner

Membership No. 048874
UDIN: 23048874BGTMB8107

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly Genlink Pharma Investments Private Limited)

CIN No : U74110MH2016PTC289765

Regd Off. Office No - 170 L, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada Navi Mumbai, 400705, Maharashtra, India.

Standalone Unaudited Financial Results for the Quarter ended 30th September 2022

INR

Sr. No.	Particulars	Three months ended 30/09/2022	Preceding three months ended 30/06/2022	Corresponding 3 Months ended 30/09/2021	Year to date figures for current period ended 30/09/2022	Year to date figures for Previous period ended 30/09/2021	Previous year ended 31/03/2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
(i)	Net Sales/Income from Operations (Net of excise duty)	10,89,000.00	10,89,000.00	9,90,000.00	21,78,000.00	19,80,000.00	40,92,000.00
(ii)	Other operating income	1,19,194.48	89,398.77	-	2,08,593.25	22,754.00	5,82,065.00
	Total Income from Operations	12,08,194.48	11,78,398.77	9,90,000.00	23,86,593.25	20,02,754.00	46,74,065.00
2	Expenses						
(i)	Cost of Material Consumed						
(ii)	Purchase of Stock in trade						
(iii)	Change in Inventory of Finished Goods, Work In progress and Stock in trade						
(iv)	Employee Benefits Expenses						
(v)	Depreciation and Amortization Expenses	1,35,212.00	1,38,153.00	1,28,211.00	2,68,365.00	256,422.00	5,11,443.00
(vi)	Finance Cost	5,11,879.00	5,21,975.00	31,84,39,179.00	10,33,854.00	31,90,01,999.00	21,65,206.47
(vii)	Other Expenses	1,95,580.80	2,17,325.90	1,10,325.00	4,13,031.70	3,45,950.00	7,80,199.98
	Total Expenses	8,42,671.80	8,72,453.90	31,86,77,715.00	17,15,250.70	31,96,04,370.00	34,56,849.45
3	Profit/(Loss) from operation before tax	3,65,522.68	3,05,944.87	-31,76,87,715.00	6,71,342.55	-31,76,01,616.00	12,17,215.55
4	Tax Expenses	64,022.00	64,022.40	35,050.00	1,28,044.00	70,100.00	1,74,200.00
5	Profit/(Loss) from ordinary activities for the period	3,01,500.68	2,41,922.47	-31,77,22,765.00	5,43,298.55	-31,76,71,716.00	10,43,015.55
6	Other Comprehensive Income						
(i)	Items that will not be reclassified to profit or loss						
(ii)	Items that will be reclassified to profit or loss						
	Total Comprehensive Income/(Loss) for the period						
7	Paid up Equity Share Capital of 10/- each	10,000.00	10,000.00	10,000.00	10,000.00	10,000.00	10,000.00
8	Earning per Share (not annualised)						
	Basic	30.15	19	-31,772.28	54.33	-31,767.17	104.30
	Diluted						

Genlink Pharma Solutions Private Limited

Date: 13/01/23




Susheel Koul

Anand Shah

Place: Navi Mumbai

Managing Director
DIN: 00925887

Director
DIN: 00597145

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

STANDALONE CASH FLOW STATEMENT FOR THE QUARTER ENDED 30th SEPTEMBER 2022

(Amount in INR)

PARTICULARS	As at 30 Sept 2022 (Unaudited)	As at 31 March 2022 (Audited)
A Cash flow from Operating Activities		
(Loss) / Net profit before Taxation	6,71,343	12,17,216
Adjustment for:		
Interest and Finance Charges	10,33,854	21,65,206
Depreciation and amortisation expenses	2,68,365	5,11,443
Interest Income	(2,08,055)	(5,57,065)
Operating Profit/(Loss) before working capital Changes	17,65,506	33,36,800
Adjustment for:		
Trade Receivables	-	26,254
Short Term Loans and Advances	-	-
Other Current Assets	(2,05,771)	32,190
Other Long Liabilities	-	-
Trade Payable	82,064	-
Other Current Liabilities	(2,49,520)	2,95,210
Provisions	-	-
Cash Generated from/(Used) in Operating Activities	13,92,280	36,90,454
Taxes Paid (net)	27,206	(1,92,024)
Net Cash Flow from/(Used) in Operating Activities	14,19,486	34,98,430
B Cash flow from Investing Activities		
Purchase of Fixed assets		
Investments		-
Sale of Fixed assets		
Loan given to Associates	(50,38,000)	
Interest Received	2,08,055	1,33,566
(Purchases)/ Sale of Investments (Net)		
Increase in long term loans & advances		
Net Cash Flow from/(Used) in Investing Activities	(48,29,944)	1,33,566
C Cash flow from Financing Activities		
Dividend and DDT		
(Decrease) / Increase in Long term borrowings	6,47,810	(17,37,572)
Proceeds from Short term borrowings	(19,43,914)	
Interest and Finance Charges	(10,33,854)	(21,65,207)
Net Cash Flow from/(Used) in Financing Activities	(23,29,958)	(39,02,779)
Net Increase/(Decrease) in Cash and Cash equivalents (A+B+C)	(57,40,417)	(2,70,783)
Opening Cash and cash equivalent		
Cash in Hand	67	67
Balance in Current Account	57,43,743	60,14,526
Balance in Fixed deposit Account	-	-
	57,43,810	60,14,593
Closing Cash and cash equivalent		
Cash in Hand	67	67
Balance in Current Account	3,326	57,43,743
Balance in Fixed deposit Account	-	-
	3,393	57,43,810

For Genlink Pharma Solutions Private limited

Anand Shah
Chairman
DIN: - 00597145
Navi Mumbai

Susheel Koul
Managing Director
DIN: - 00925887
Navi Mumbai

Itishree Garg
Company Secretary &
Compliance officer
Membership no-

Date: 13-01-2023

Date: 13-01-2023

ACS 46259
Navi Mumbai
Date: 13-01-2023

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

DISCLOSURE UNDER REGULATION 52(4) OF SEBI (LODR), 2015

With reference to Regulation 52 (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find disclosure as under for the For Half year ended 30th September 2022.

1. Debt-equity ratio - 60.65 times
2. Debt service coverage ratio - 0.27 times
3. Interest service coverage ratio - 1.73 times
4. Outstanding redeemable preference shares (quantity and value) - The Company does not have any outstanding redeemable preference shares.
5. Capital redemption reserve/debenture redemption reserve - Nil
6. Net worth - The net worth of the Company is Rs 45.42 lacs
7. Net profit after tax
Net profit after tax of the Company is Rs. 5.43 lacs
8. Earnings per share
Earnings per share of the Company is Rs. 54.33
9. Current ratio - 0.02 times
10. Long term debt to working capital - NA
11. Current liability ratio - NA
12. Total debts to total assets - 0.97 times
13. Debtors turnover - NA
14. Inventory turnover - NA
15. Operating margin (%) - 90.61 %
16. net profit margin (%) - 24.94
17. Bad debts to Account receivable ratio - Nil

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

For Genlink Pharma Solutions Private Limited



Itishree Garg
Company Secretary and Compliance Officer
Membership No. A 46259



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

STATEMENT OF VALUE OF PLEDGED SECURITIES AS ON 30TH September, 2022

We hereby state that the Company maintains as on 30th September, 2022 such pledged securities as enlisted below:

1. 563,497 Equity Shares of Enaltec Labs Private Limited held by Genlink Pharma Solutions Private Limited at value of Rs. Nil per share vide Valuation Report by Vira Financial Advisors Private Limited aggregating to Rs. Nil.
2. 5,923 Equity Shares of Enaltec Labs Private Limited held by Mr. Anand Shah at value of Rs. Nil per share vide Valuation Report by Vira Financial Advisors Private Limited aggregating to Rs. Nil.
3. 5,923 Equity Shares of Enaltec Labs Private Limited held by Mr. Susheel Koul at value of Rs. Nil per share vide Valuation Report by Vira Financial Advisors Private Limited aggregating to Rs. Nil.

For Genlink Pharma Solutions Private Limited



Itishree Garg
Company Secretary and Compliance Officer
Membership No. A 46259



Date: 13/01/2023
Place: Navi Mumbai

Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002, India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

To,

Stock Exchange (s)

As per requirement of SEBI circular no. SEBI/HO/MIRSD/MIRSD_CRADT/CIR/P/2022/67 dated May 19, 2022 & based on examination of books of accounts and other relevant records/documents of **M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**, (CIN: U74110MH2016PTC280765) for **quarter ending on 30th September 2022 (unaudited)**, having its registered office at 1701, 17th Floor, Kesar Solitaire, Plot No 5, Sector 19, Sanpada, Navi Mumbai – 400 705, Maharashtra, India, we hereby certify security cover certificate given below.

Security Cover Certificate for listed debt securities

As per Regulation 54 read with regulation 56 (1) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with aforementioned circular no.

Sr. No.	Particulars	Amount
I.	Assets available for secured Debt Securities' – (secured by either pari passu or exclusive charge on assets) (refer note below)	Nil
	<ul style="list-style-type: none">Property Plant & EquipmentCapital Work in ProgressRight of use AssetsGood Will	Nil
	<ul style="list-style-type: none">Intangible AssetsIntangible Assets under developmentInvestmentsLoansInventoriesTrade ReceivablesCash & Cash EquivalentsBank balances other than Cash & Cash EquivalentsOthers	Nil



Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002, India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

ii	Liabilities for secured Debt Securities' – (secured by either pari passu or exclusive charge on assets) (refer note below)	25.00 crore
	<ul style="list-style-type: none">• Debt Securities to which this certificate pertains• Other debt sharing pari-passu charge with above debt• Other debt• Subordinated debt• Borrowings• Bank• Debt securities• Others• Trade Payables• Lease Liabilities• Provisions• Others	25.00 crore Nil
iii	• Exclusive Security Cover Ratio (Value of Assets having exclusive charge / Outstanding Value of corresponding debt + Interest Accrued) (refer note below) (Nil /25 cr)	Nil
iv	• Pari – Passu Security Cover Ratio	N.A.

Note 1: The **debt is secured** against 5,63,497 Equity Shares of Enaltec Labs Private Limited Cost of which is Rs. 24.89 Crores, as per valuation report dated 01.12.2021, the **present market value for Assets charged on exclusive basis is NIL**

Note 2: As per Common Shareholders Agreement dated January 18, 2022, specifically clause 12 and sub clause 12.4, and as per waiver letters dated January 22, 2022 and February 2, 2022 the NCD holder viz. Riverstreet and the Debenture Trustee viz. Vistra ITCL (India) Ltd., respectively, have waived their rights under the Debenture Trust Deed dated March 17, 2017 and as per legal opinion dt.30.11.2022 and management clarification dt.30.11.2022 the management is of the opinion that no enforceable liability to pay premium of Rs.12,71,575/- per NCD upto 30th September 2022. Accordingly, NCD shall now be redeemed at future date and the premium shall be computed based on the valuation of the underlying pledge shares. Since the value is not determinable today, hence are contingent in nature and not considered.



FOR SHANKARLAL JAIN & ASSOCIATES LLP
CHARTARED ACCOUNTATS
FIRM REG NO. 109901W/W100082

SATISH JAIN
Partner
Membership No. 048874
UDIN: 23048874BGTMBB1661

Place: Mumbai
Date 13/01/2023